Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b.

Riggins RB, Thomas KS, Ta HQ, Wen J, Davis RJ, Schuh NR, Donelan SS, Owen KA, Gibson MA, Shupnik MA, Silva CM, Parsons SJ, Clarke R, Bouton AH.

Cancer Res. 2006 Jul 15;66(14):7007-15.

2.

Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

Kurokawa H, Arteaga CL.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Review.

PMID:
11916237
3.

Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111. Review.

4.

Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells.

Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W.

Steroids. 2009 Jul;74(7):586-94. doi: 10.1016/j.steroids.2008.11.020. Epub 2008 Dec 7. Review.

PMID:
19138696
5.
6.

Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer.

Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ.

Breast Cancer Res. 2000;2(3):203-10. Epub 2000 Mar 7. Review.

7.

Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways.

Fox EM, Andrade J, Shupnik MA.

Steroids. 2009 Jul;74(7):622-7. doi: 10.1016/j.steroids.2008.10.014. Epub 2008 Nov 5. Review.

8.

Protein tyrosine phosphatases as novel targets in breast cancer therapy.

Nunes-Xavier CE, Martín-Pérez J, Elson A, Pulido R.

Biochim Biophys Acta. 2013 Dec;1836(2):211-26. doi: 10.1016/j.bbcan.2013.06.001. Epub 2013 Jun 10. Review.

PMID:
23756181
9.

Cas proteins: dodgy scaffolding in breast cancer.

Tornillo G, Defilippi P, Cabodi S.

Breast Cancer Res. 2014;16(5):443. Review.

10.

ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.

Mahajan K, Mahajan NP.

Oncogene. 2015 Aug 6;34(32):4162-7. doi: 10.1038/onc.2014.350. Epub 2014 Oct 27. Review.

11.

MED1 may explain the interaction between receptor tyrosine kinases and ERα66 in the complicated network of Tamoxifen resistance.

Mansouri S, Naghavi-Al-Hosseini F, Farahmand L, Majidzadeh-A K.

Eur J Pharmacol. 2017 Jun 5;804:78-81. doi: 10.1016/j.ejphar.2017.03.026. Epub 2017 Mar 16. Review.

PMID:
28322840
12.

Fyn is an important molecule in cancer pathogenesis and drug resistance.

Elias D, Ditzel HJ.

Pharmacol Res. 2015 Oct;100:250-4. doi: 10.1016/j.phrs.2015.08.010. Epub 2015 Aug 21. Review.

PMID:
26305432
13.

CAS proteins in normal and pathological cell growth control.

Tikhmyanova N, Little JL, Golemis EA.

Cell Mol Life Sci. 2010 Apr;67(7):1025-48. doi: 10.1007/s00018-009-0213-1. Epub 2009 Nov 25. Review.

14.

CAS proteins in health and disease: an update.

Nikonova AS, Gaponova AV, Kudinov AE, Golemis EA.

IUBMB Life. 2014 Jun;66(6):387-95. doi: 10.1002/iub.1282. Epub 2014 Jun 24. Review.

Supplemental Content

Support Center